Cassava Sciences (SAVA) News Today $2.33 +0.08 (+3.33%) Closing price 03:59 PM EasternExtended Trading$2.26 -0.07 (-2.80%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Cassava Sciences (NASDAQ:SAVA) Announces Quarterly Earnings ResultsAugust 18, 2025 | marketbeat.comCassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | finanznachrichten.deCassava Sciences reports Q2 EPS (92c) vs 13c last yearAugust 14, 2025 | msn.comCassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical OfficerAugust 7, 2025 | globenewswire.comGinkgo Bioworks Holdings Q2 Earnings PreviewAugust 6, 2025 | msn.comCassava Sciences Announces Positive Preclinical ResultsAugust 6, 2025 | theglobeandmail.comCassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related EpilepsyAugust 4, 2025 | globenewswire.comGallacher Capital Management LLC Decreases Stock Holdings in Cassava Sciences, Inc. (NASDAQ:SAVA)July 23, 2025 | marketbeat.comSAVA - Cassava Sciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMCassava Sciences presents poster at TSC 2025 on SimufilamJune 30, 2025 | msn.comCassava Presents Promising Preclinical Simufilam Data at TSC Alliance MeetingJune 30, 2025 | globenewswire.comSAVA Stock Price for Cassava Sciences Inc - MorningstarJune 28, 2025 | morningstar.comMWhy cassava could be a great addition to a balanced dietJune 26, 2025 | msn.comTwo Sigma Investments LP Has $1.33 Million Position in Cassava Sciences, Inc. (NASDAQ:SAVA)June 5, 2025 | marketbeat.comTwo Sigma Advisers LP Invests $1.43 Million in Cassava Sciences, Inc. (NASDAQ:SAVA)June 1, 2025 | marketbeat.comCassava Sciences Inc.May 15, 2025 | barrons.comCassava Technologies, Zindi collaborate on AI servicesMay 12, 2025 | msn.comNew report finds concerning levels of lead in popular cassava itemsMay 12, 2025 | yahoo.comCassava Reports Q1 2025 Financials Results, Provides Business UpdateMay 9, 2025 | finance.yahoo.comInvesco Ltd. Trims Stock Position in Cassava Sciences, Inc. (NASDAQ:SAVA)May 8, 2025 | marketbeat.comZindi Teams Up with Cassava to Spotlight African AI TalentMay 6, 2025 | msn.comZindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovationMay 5, 2025 | msn.comCassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSCMay 1, 2025 | globenewswire.comCassava Sciences appoints new SVP of Clinical DevelopmentApril 23, 2025 | investing.comCassava Sciences chief medical officer James Kupiec to retireApril 22, 2025 | markets.businessinsider.comCassava's Chief Medical Officer to retireApril 21, 2025 | msn.comCassava Sciences Chief Medical Officer Kupiec RetiresApril 21, 2025 | marketwatch.comCassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical DevelopmentApril 21, 2025 | globenewswire.comShort Interest in Cassava Sciences, Inc. (NASDAQ:SAVA) Declines By 17.8%April 3, 2025 | marketbeat.comNotable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focusMarch 30, 2025 | msn.comCassava Sciences must face malicious prosecution lawsuit over Alzheimer's drugMarch 26, 2025 | reuters.comHC Wainwright Reiterates Neutral Rating for Cassava Sciences (NASDAQ:SAVA)March 26, 2025 | marketbeat.comCassava ends simufilam Alzheimer’s programme after second Phase III failureMarch 26, 2025 | finance.yahoo.comCassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpointMarch 25, 2025 | markets.businessinsider.comCassava Sciences to discontinue all efforts to develop simufilam in Alzheimer’sMarch 25, 2025 | markets.businessinsider.comCassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains HopefulMarch 25, 2025 | msn.comCassava to phase out Alzheimer’s program by Q2March 25, 2025 | msn.comCassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be DiscontinuedMarch 25, 2025 | marketwatch.comCassava to discontinue development of Alzheimer's disease drugMarch 25, 2025 | msn.comCassava Sciences' controversial Alzheimer's drug fails in second late-stage studyMarch 25, 2025 | msn.comCassava Sciences Reports Topline Phase 3 REFOCUS-ALZ DataMarch 25, 2025 | globenewswire.comCassava Sciences: Downside From Alzheimer's Results Still Possible Despite New DevelopmentsMarch 21, 2025 | seekingalpha.comCassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comHC Wainwright Lifts Earnings Estimates for Cassava SciencesMarch 8, 2025 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Given Neutral Rating at HC WainwrightMarch 5, 2025 | marketbeat.comCassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term ValueMarch 4, 2025 | seekingalpha.comH.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might revealMarch 4, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)March 4, 2025 | markets.businessinsider.comCassava Sciences, Inc.: Cassava Sciences Reports 2024 Financial Results and Provides Business UpdateMarch 4, 2025 | finanznachrichten.de Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SAVA Media Mentions By Week SAVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAVA News Sentiment▼0.940.97▲Average Medical News Sentiment SAVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAVA Articles This Week▼16▲SAVA Articles Average Week Get the Latest News and Ratings for SAVA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cassava Sciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Corvus Pharmaceuticals News Today Kamada News Today Aura Biosciences News Today I-Mab News Today Y-mAbs Therapeutics News Today Aquestive Therapeutics News Today Vigil Neuroscience News Today Olema Pharmaceuticals News Today Rocket Pharmaceuticals News Today Zhengye Biotechnology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAVA) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access